Potent and selective DYRK1A/B inhibitor (IC50 values are 22 and 68 nM respectively). Selective for DYRK1A/B over a panel of other kinases. Reduces accumulation of quiescent Panc1 pancreatic cancer cells in G0 under serum free conditions. Also induces DNA damage and apoptosis in quiescent Panc1 cells.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 498.32. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.01 mL||10.03 mL||20.07 mL|
|5 mM||0.4 mL||2.01 mL||4.01 mL|
|10 mM||0.2 mL||1 mL||2.01 mL|
|50 mM||0.04 mL||0.2 mL||0.4 mL|
References are publications that support the products' biological activity.
Ewton et al (2011) Inactivation of mirk/dyrk1b kinase targets quiescent pancreatic cancer cells. Mol.Cancer Ther. 10 2104 PMID: 21878655
Anderson et al (2013) Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors. Bioorg.Med.Chem.Lett. 15 6610 PMID: 24239188
If you know of a relevant reference for TC-S 7004, please let us know.
View Related Products by Product Action
Keywords: TC-S 7004, supplier, TC-S7004, Mirk, DYRK1B, DYRK1A, potent, inhibitors, inhibits, DYRK, DYRK, Tocris Bioscience
Citations for TC-S 7004
Citations are publications that use Tocris products.
Currently there are no citations for TC-S 7004. Do you know of a great paper that uses TC-S 7004 from Tocris? If so please let us know.
TC-S 7004 Reviews
Average Rating:(Based on 0 Reviews)
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.